Seattle Biotech Myosana Raises $5M to Develop Advanced Gene Therapy for Duchenne Muscular Dystrophy

Myosana Therapeutics, a Seattle biotech co-founded by University of Washington researchers, raised $5 million to advance a novel gene therapy candidate targeting Duchenne muscular dystrophy (DMD). The company aims to develop a gene delivery platform that can handle larger DNA segments compared to current standard methods, potentially improving treatment options against DMD.